Alder BioPharmaceuticals Inc. (ALDR) Insider Sells $280,800.00 in Stock

Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) insider Randall C. Schatzman sold 10,000 shares of Alder BioPharmaceuticals stock in a transaction dated Monday, July 25th. The shares were sold at an average price of $28.08, for a total transaction of $280,800.00. Following the completion of the sale, the insider now owns 124,768 shares in the company, valued at approximately $3,503,485.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Several brokerages have recently issued reports on ALDR. Jefferies Group reiterated a “buy” rating and issued a $61.00 target price on shares of Alder BioPharmaceuticals in a research report on Thursday, June 9th. Brean Capital reiterated a “positive” rating on shares of Alder BioPharmaceuticals in a research report on Wednesday. Zacks Investment Research upgraded shares of Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 30th. Wells Fargo & Co. began coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, April 21st. They issued an “outperform” rating on the stock. Finally, Credit Suisse Group AG reiterated an “outperform” rating and issued a $40.00 target price on shares of Alder BioPharmaceuticals in a research report on Tuesday, March 29th. Six equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $47.60.

Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) traded up 3.46% during trading on Wednesday, hitting $30.49. 1,218,349 shares of the stock traded hands. The stock’s market cap is $1.52 billion. Alder BioPharmaceuticals Inc. has a 52-week low of $15.82 and a 52-week high of $47.90. The company’s 50 day moving average price is $26.77 and its 200-day moving average price is $25.15.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings data on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by $0.04. The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $1.14 million. The business’s revenue was up 112900.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.46) EPS. Equities research analysts forecast that Alder BioPharmaceuticals Inc. will post ($3.25) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Alder BioPharmaceuticals stock. Nationwide Fund Advisors increased its position in Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) by 103.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 30,380 shares of the biopharmaceutical company’s stock after buying an additional 15,457 shares during the period. Nationwide Fund Advisors owned approximately 0.07% of Alder BioPharmaceuticals worth $1,003,000 at the end of the most recent quarter.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.